{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:37:51Z","timestamp":1767137871091,"version":"build-2238731810"},"reference-count":10,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Patients with burns are at an increased risk of multidrug\u2010resistant pathogens including\n                      <jats:styled-content style=\"fixed-case\">\n                        <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      <\/jats:styled-content>\n                      and may need specialized dosing regimens due to alterations in physiology due to their injuries.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Therefore, we conducted a single\u2010dose, open\u2010label, pharmacokinetic study of ceftolozane (2\u2009g)\/tazobactam (1\u2009g) infused over 60\u2009min in six patients with partial\u2010 or full\u2010thickness burns and central line access. Serial blood samples were obtained at the following time points: 0 (predose) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24\u2009h following the start of infusion for determination of plasma drug concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Similar estimates of clearance (CL) were observed between the groups, and as a consequence the half\u2010life (T1\/2) was longer in the six patients with burns in the current study compared to previous studies of healthy volunteers on average. Although these mean comparisons suggest similarity in exposure based on area under the curve (AUC) and maximum concentration (Cmax), it is important to recognize that the interindividual variability is approximately 2\u2010 to 5\u2010fold higher in patients with burns compared to healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We did not find sufficient deviations in the concentrations of ceftolozane\/tazobactam to recommend an empiric dose adjustment for patients with burns. However, this finding is limited by our small sample size and lack of clinical outcome data. Therefore, we also provide a conditional recommendation to conduct therapeutic drug monitoring to adjust ceftolozane\/tazobactam dosing or to switch to a continuous infusion approach in cases of a suboptimal clinical response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70076","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T17:18:28Z","timestamp":1762795108000},"page":"774-779","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Ceftolozane\/Tazobactam in Patients With Partial\u2010 and Full\u2010Thickness Skin Burns"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5616-8246","authenticated-orcid":false,"suffix":"2nd","given":"Ronald G.","family":"Hall","sequence":"first","affiliation":[{"name":"Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center  Dallas Texas USA"},{"name":"Clinical Pharmacology and Experimental Therapeutics Center of Excellence  Dallas Texas USA"},{"name":"Dose Optimization and Outcomes Research Program  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-8702","authenticated-orcid":false,"given":"Levi","family":"Hooper","sequence":"additional","affiliation":[{"name":"College of Pharmacy University of Michigan  Ann Arbor Michigan USA"},{"name":"Abbvie Inc.  North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-8331","authenticated-orcid":false,"given":"Sharmila","family":"Dissanaike","sequence":"additional","affiliation":[{"name":"School of Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"},{"name":"University of New Mexico School of Medicine  Albuquerque New Mexico USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-0646","authenticated-orcid":false,"given":"John A.","family":"Griswold","sequence":"additional","affiliation":[{"name":"School of Medicine Texas Tech University Health Sciences Center  Lubbock Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-7063","authenticated-orcid":false,"given":"Raja Reddy","family":"Kallem","sequence":"additional","affiliation":[{"name":"Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center  Dallas Texas USA"},{"name":"Clinical Pharmacology and Experimental Therapeutics Center of Excellence  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-7022","authenticated-orcid":false,"given":"Indhumathy","family":"Subramaniyan","sequence":"additional","affiliation":[{"name":"Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center  Dallas Texas USA"},{"name":"Clinical Pharmacology and Experimental Therapeutics Center of Excellence  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9338-4143","authenticated-orcid":false,"given":"William C.","family":"Putnam","sequence":"additional","affiliation":[{"name":"Jerry H. Hodge School of Pharmacy Texas Tech University Health Sciences Center  Dallas Texas USA"},{"name":"Clinical Pharmacology and Experimental Therapeutics Center of Excellence  Dallas Texas USA"},{"name":"Dose Optimization and Outcomes Research Program  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath P.","family":"Pai","sequence":"additional","affiliation":[{"name":"College of Pharmacy University of Michigan  Ann Arbor Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix682"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0000000000000147"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289586"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irad123"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2020.122354"},{"key":"e_1_2_10_7_1","unstructured":"Services USDoHaH Administration FaD \u201cBioanalytical Methods Validation Guidance for Industry \u201d(2018) https:\/\/www.fda.gov\/media\/70858\/download."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.429"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121737"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106299"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.70019"}],"updated-by":[{"DOI":"10.1002\/phar.70091","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000}}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:41:03Z","timestamp":1764585663000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/phar.70076"],"URL":"https:\/\/doi.org\/10.1002\/phar.70076","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}